Iproniazid

Overview

Iproniazid is an orally active, irreversible, non-selective monoamine oxidase ( MAO ) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone ( HY-B1756 )-induced Apoptosis . Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity.

Application

Products | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Depression | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Signaling Pathways > Neuronal Signaling | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Endocrinology | Products > Signaling Pathways > Monoamine Oxidase | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-B0886A
• CAS No.: 54-92-2
• Molecular Formula: C9H13N3O
• Molecular Weight: 179.22
• Purity: 99.91%
• Storage: -20°C, stored under nitrogen * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
• Solubility: ≥ 2.5 mg/mL (13.95 mM); Clear solution
• Availability: In-stock

Source

Original product source